Emergent Biosolutions Inc (EBS) - News Archive

Emergent Biosolutions Inc, a renowned global leader in developing and manufacturing medical countermeasures, has been facing numerous challenges and setbacks this year. A closer look at recent articles and market insigh...

In a bid to revitalize its financial health and position itself for long-term success, Emergent BioSolutions Inc. has embarked on a multi-year transformation plan. The company, a leading player in the healthcare sector,...

Strategic Reinforcement: Emergent BioSolutions Secures $250M in Contract Modifications to Enhance U.S. Medical Countermeasure StockpilesGAITHERSBURG, Md., July 02, 2024 Emergent BioSolutions Inc. (NYSE: EBS) has announc...

Emergent Biosolutions Inc (EBS), a global biopharmaceutical company, has made significant strides in the market, with its share value outperforming the industry. This article aims to provide an overview of recent develo...

GAITHERSBURG, Md., June 20, 2024 Emergent BioSolutions Inc. (NYSE: EBS), a global biopharmaceutical company, has announced the sale of its Baltimore-Camden manufacturing site to an affiliate of Bora Pharmaceuticals Co.,...

Gaithersburg, Md., June 6, 2024In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is taking significant strides to address the opioid epidemic in the United States. As part of thei...

Emergent BioSolutions Inc., a global life sciences company that specializes in emergencies of health and is known for its diverse portfolio of medicines and medical countermeasures, recently announced an amendment to it...

Embracing Multi-Sectoral Action to Combat the Ongoing Opioid CrisisThe opioid crisis in the United States continues to escalate, with devastating consequences for public health and safety. Emergency BioSolutions Inc. (E...

Emergent BioSolutions Baltimore Bayview Manufacturing Facility Achieves No Action Indicated Status by FDAEmergent BioSolutions Inc. (EBS), a global specialty pharmaceutical company headquartered in Gaithersburg, Marylan...

Emergent BioSolutions Inc, a Maryland-based life sciences company, announced it has been awarded an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract, which has a maximum value of $235.8 million. The...

In a significant boost to Emergent BioSolutions Inc. (NYSE: EBS), the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a contract option worth $75 million. This contract aims to pro...